1.	Polkowska-Pruszynska B, Gerkowicz A, Szczepanik-Kulak P. SMALL INTESTINAL BACTERIAL OVERGROWTH IN SYSTEMIC SCLEROSIS: A REVIEW OF THE LITERATURE. Archives of Dermatological Research (2019) 311:1-8. https://doi.org/10.1007/s00403-018-1874-0.
2.	Erdogan A, Rao SS, Gulley D, Jacobs C, Lee YY, Badger C (2015) Small intestinal bacterial overgrowth: duodenal aspiration vs glucose breath test. Neurogastroenterol Motil 27(4):481–489. https://doi.org/10.1111/nmo.12516
3.	Savarino E, Mei F, Parodi A, Ghio M, Furnari M, Gentile A et al (2013) Gastrointestinal motility disorder assessment in systemic sclerosis. Rheumatology 52(6):1095–1100. https://doi. org/10.1093/rheumatology/kes429
4.	Fynne L, Worsøe J, Gregersen T, Schlageter V, Laurberg S, Krogh K (2011) Gastrointestinal transit in patients with systemic sclerosis. Scand J Gastroenterol 46(10):1187–1193. 
https://doi. org/10.3109/00365521.2011.603158
5.	 Gemignani L, Savarino V, Ghio M, Parodi A, Zentilin P, de Bortoli N et al (2013) Lactulose breath test to assess oro-cecal transit delay and estimate esophageal dysmotility in scleroderma patients. Semin Arthritis Rheum 42(5):522–529. https://doi.org/10.1016/j. semarthrit.2012.09.004
6.	Tauber M, Avouac J, Benahmed A, Barbot L, Coustet B, Kahan A et al (2014) Prevalence and predictors of small intestinal bacterial overgrowth in systemic sclerosis patients with gastrointestinal symptoms. Clin Exp Rheumatol 32(6 Suppl 86):S–S82
7.	Parodi A, Sessarego M, Greco A, Bazzica M, Filaci G, Setti M et al (2008) Small intestinal bacterial overgrowth in patients suffering from scleroderma: clinical effectiveness of its eradication. Am J Gastroenterol 103:1257–1262. https://doi.org/10.111 1/j.1572-0241.2007.01758.x
8.	Marie I, Ducrotté P, Denis P, Menard JF, Levesque H (2009) Small intestinal bacterial overgrowth in systemic sclerosis. Rheumatology 48(10):1314–1319. https://doi.org/10.1093/rheumatology/ kep226
9.	Lorenzo Gemignani, MD,* Vincenzo Savarino, MD,* Massimo Ghio, MD. Lactulose Breath Test to Assess Oro-cecal Transit delay and Estimate Esophageal dysmotility in Scleroderma Patients. Seminars in Arthritis and Rheumatism
Volume 42, Issue 5, April 2013, Pages 522-529. https://doi.org/10.1016/j.semarthrit.2012.09.004
10. Edward J. Krajicek, MD, and Stephanie L. Hansel, MD. Small Intestinal Bacterial Overgrowth: A Primary Care Review. Mayo Clinic. 2016. https://doi.org/10.1016/j.mayocp.2016.07.025
11. Abimbola Adike, MD, John K. DiBaise, MD. Small Intestinal Bacterial Overgrowth Nutritional Implications, Diagnosis, and Management. Gastroenterol Clin N Am 2017. https://doi.org/10.1016/j.gtc.2017.09.008
12. Kookwan Sawadpanich, Pisit Soison, Kitti Chunlertrith, Pisaln Mairiang. Prevalence and associated factors of small intestinal bacterial overgrowth among systemic sclerosis patients. International Journal of Rheumatic Diseases. 2017. DOI: 10.1111/1756-185X.13495
13. Di Ciaula A, Covelli M, Berardino M, et al. Gastrointestinal sympâ€ toms and motility disorders in patients with systemic scleroderma. BMC Gastroenterol. 2008;8:7.
14. Domsic R, Fasanella K, Bielefeldt K. Gastrointestinal manifestations of systemic sclerosis. Dig Dis Sci. 2008;53(5):1163â€1174.
15. Gasbarrini A, Corazza GR, Gasbarrini G, et al. Methodology and indiâ€ cations of H2â€breath testing in gastrointestinal diseases: the Rome Consensus Conference. Aliment Pharmacol Ther. 2009;29(suppl 1):1â€49


